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1. Introduction   
Many changes in the functioning of the thyroid gland occur during pregnancy and some 
diseases of the thyroid gland can affect both the pregnant woman and the fetus. (Casey et 
all., 2006; Lazarus & Premawardhana, 2005; Poppe et all., 2007). Hypothyroidism is the most 
serious disorder of those occurring during pregnancy, and it might go unnoticed as some 
‘nonspecific’ problem. Pregnant women with subclinical hypothyroidism seem to escape 
early clinical detection (Lazarus, 2002). While the hyperfunction during pregnancy usually 
manifests itself by clinical symptoms or a relapse of a previously cured disease (mostly 
Graves - Basedow) (Abalovich et all., 2007), lowered functioning is much more dangerous 
because of its non-specific symptoms. During the 1st trimester, the fetus is completely 
dependent upon thyroxin produced by the mother (Smallridge & Landerson, 2001). Even a 
small unnoticed malfunction of the thyroid gland, which doesn’t have to endanger the 
course of the pregnancy, can affect the psychomotor developement of the child (Morreale de 
Escobar et all., 2004; Mitchell & Klein, 2004)). Some women with subclinical hypothyroidism 
are absolutely asymptomatic and there is no reliance on the clinical image, while diagnostic 
of thyroid dysfunction (Klein et all., 2001).  
Malfunction of the thyroid gland during pregnancy is long-term, and still not a sufficiently 
solved problem (Lazarus, 2002). On many pages of scientific literature and specialist 
literature there are still new arguments to systematically screen pregnant women for thyroid 
dysfunction and asymptomatic chronic thyroiditis in order to give such women the 
appropriate treatment (Surks et all., 2004). Results of surface population screenings are 
slightly varied, depending upon on level of medical care and approach to prevention, 
geographical conditions, supplementing with iodine, and other circumstances (including 
used diagnostic criteria) (Vaidya et all., 2007). Evaluating thyroidal function during 
pregnancy is difficult, considering the other differing influences of pregnancy.  
Guidelines for management of thyroid dysfunction during pregnancy and postpartum 
(Abalowich et al. 2007) recommend not universal but only case finding screening. The first aim 
of the study was to assess the value of this recommendation. The other aim was to introduce 
an estimation of thyroid dysfunction during pregnancy, selection of suitable biochemical 
markers and determination of reference intervals for these markers in pregnancy. 
2. Investigation of thyroidal dysfunction in pregnancy 
In cooperation with General insurance company in Czech Republic was in 2009 started a 
pilot project for universal screening of thyroid dysfunction among women in the first 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
38
trimester of pregnancy. A pilot project was performed during 2009-2010 in 13 regions, (only 
4 regions in 2010) of the Czech Republic. The data from 3577 pregnant women with 
sufficient iodine intake were available. The blood for TSH (thyroid stimulating hormone), 
TPO Ab (antibodies to thyroid peroxidase) and FT4 (free thyroxine) estimation was collected 
in 9-11 week of pregnancy. All participating pregnant women gave informed written 
consent with this subsequent investigation. 
2.1 Conditions for screening 
First question is what we want to find? Which disorders are mostly indicated in pregnancy 
and what is really danger for pregnant women. Former studies resolve problems, which 
laboratory parameters are the best for investigation, the sampling of blood from pregnant 
women timing and also applicability of commonly used reference intervals for each 
parameter (Lazarus & Premawardhana, 2005;  Poppe et all., 2007). Iodine supplementation is 
also usually asked (Glinoer et all., 1995).  
2.1.1 Thyroid disorders in pregnant women 
Evaluating thyroidal function during pregnancy is difficult, considering the other differing 
influences of pregnancy (Dayan et all., 2002; Lazarus, 2002).  New thyroid nodules should be 
aggressively investigated during pregnancy because of a high incidence of malignancy. 
Radioactive Iodine is contraindicated in pregnancy. Nursing mothers who have radioactive 
iodine uptake scans should pump and discard their milk for 48-72 hours after the test. 
2.1.1.1 Hypothyroidism 
Hypothyroidism is the most serious disorder of those occurring during pregnancy, and it 
might go unnoticed as some ‘nonspecific’ problem. Pregnant women with subclinical 
hypothyroidism seem to escape early clinical detection. The implications are staggering 
when one considers that there is a significant increase in intrauterine deaths, spontaneous 
abortions, premature births, and pre-eclampsia; also the development of the fetus, such as 
major malformations and loss of IQ (Haddow et all., Pop et all., 2003). It has been clearly 
proven that even slight (subclinical) hypothyroidism affects not only the course of 
pregnancy, but (especially later-on) the neuropsychological development of the child. 
Symptoms of hypothyroidism (fatigue, lowered performance, sleepiness, psychological 
lability) can also accompany the physiological pregnancy; some women with subclinical 
hypothyroidism are absolutely asymptomatic and there is no reliance on the clinical image, 
while diagnostic of functional failure. Untreated patients with hypothyroidism rarely 
conceive and carry a pregnancy. Treated hypothyroidism usually has no associated 
pregnancy complications. Patients will require increased levothyroxine doses during their 
pregnancies. Monitoring of thyroid function tests each trimester and at other clinically 
indicated times is recommended (Dashe 2005).  
Prenatal vitamins can decrease the absorption of levothyroxine. 
2.1.1.2 Hyperthyroidism 
The hyperfunction during pregnancy usually manifests itself by clinical symptoms or a 
relapse of a previously cured disease. 95% of hyperthyroidism in pregnancy is secondary to 
Graves - Basedow disease. A good pregnancy outcome can be expected in patients with 
good control. Untreated hyperthyroidism is associated with decreased fertility, an increased 
rate of miscarriage, intrauterine growth retardation (IUGR), premature labor, and perinatal 
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mortality (Poppe et all., 2007). Poorly controlled thyrotoxicosis is associated with thyroid 
storm especially at labor and delivery. Beta blockers and propylthiouracil (PTU) can be 
safely used in pregnancy and in nursing mothers. PTU crosses the placenta but does not 
usually cause fetal hypothyroidism and goiter unless used in high doses. Treatment goals 
favor mild hyperthyroidism over hypothyroidism. Like other immune mediated diseases in 
pregnancy, Grave’s disease tends to improve in the third trimester. Exacerbations may occur 
in the first trimester and postpartum. Neonatal and fetal thyrotoxicosis may occur because 
of transplacental passage of thyroid stimulating antibodies. 
2.1.1.3 Postpartum thyroiditis 
Postpartum thyroiditis is a destructive autoimmune thyroiditis that begins with a period of 
hyperthyroidism followed by a period of hypothyroidism (Negro et all., 2007). The gland is 
often enlarged. There is usually complete recovery but a chance of recurrence in subsequent 
pregnancies exists. 80-85% of patients will have positive antithyroid antibodies. A 
radioactive iodine uptake scan can differentiate postpartum thyroiditis from an exacerbation 
of Graves- Basedow disease.  
TPO Ab antibodies are markers of autoimmune process in the thyroid gland, their 
determination is diagnostically and prognostically important. Presence of TPO Ab during 
pregnancy also alerts to the danger of development of postpartum tyreoiditidis (Nicholson 
at all., 2006; Dosiou et all., 2008); about 50% of TPO Ab positive women have some thyroid 
dysfunction after delivery (Premawardhana et all., 2004; Nicholson at all., 2006), so it is 
necessary to follow-up these women. Postpartum thyroiditis is in an important 
consideration in women with postpartum depression. 
2.1.1.4 Hyperemesis gravidarum 
Hyperemesis is associated with abnormal thyroid function tests in a significant number of 
cases. Hyperthyroidism may be the cause of hyperemesis or hyperemesis may be the cause 
of the hyperthyroidism (Goodwin et all., 1992). 
2.1.2 Iodine supplementation in pregnancy 
The iodine requirement during pregnancy is sharply elevated because of an increase in 
maternal thyroxine production to maintain maternal euthyroidism and to transfer thyroid 
hormone to the fetus, iodine needs to be transferred to the fetus for fetal thyroid hormone 
production in later gestation and a probable increase in renal iodine clearance. The 
recommended dietary allowance for nonpregnant, nonlactating women aged 14 year is 150 
µg/d, for pregnant women is it 220 µg/d (Zimmermann & Delange, 2004),. In Czech 
Republic has been iodized salt in regular use since the 1950s, a good level of iodine 
supplementation can be expected also on Zamrazil study (Zamrazil, 2004). Women in this 
study were in addition supplemented by 100-150 ug of iodide daily. 
2.1.3 Timing of the blood taking 
The study group consists of 3 577 asymptomatic pregnant women (in their 9th – 11th week of 
pregnancy, 99% Caucasian) who were undergoing their first trimester prenatal screening. In 
the pilot project were used laboratories, which were able to investigate serum for the first 
trimester screening (investigation of PAPP-A and free β hCG) and simultaneously in the 
same sample determine TSH (thyroid stimulating hormone), TPO Ab (antibodies to thyroid 
peroxidase) and FT4 (free thyroxine). 
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2.1.4 Selection of laboratory parameters 
The thyroid gland increases slightly in size during pregnancy. 
Determining TSH in the serum is a basic searching procedure in the diagnosis of function of 
the thyroid gland in the general population. Its regulation is based on feedback, however 
during pregnancy there are also other mechanisms taking place. Suppressed serum TSH 
concentration during gestation follow hyperthyroidism as well as hyperemesis gravidarum 
or high hCG levels. Lower serum TSH in pregnancy is influenced by the thyrotropic activity 
of elevated circulating human chorionic gonadotropin concentrations, mainly in the first 
trimester (Abalovich 2007; Dashe 2005).  
The comparision two groups of women, on pregnant and the other nonpregnant shows shift 
levels of TSH in pregnancy. On Fig.1 is possible to see only low levels of TSH. 
 
 
Fig. 1. Comparision TSH in group of pregnant (first trimester of pregnancy) and 
nonpregnant women in part with low TSH levels 
In the group of pregnant women, with suppressed TSH, the average level of hCG was 
almost double (M=95.6 mg/ml), in comparison with the group with TSH in the reference 
interval (M=68.9 mg/ml) or with TSH >3.67mU/l (M=62.1 mg/ml). Differences between the 
normal and raised TSH groups in hCG levels were not significant at p<0.050. The other 
authors confirm that sub-normal serum TSH levels in the first trimester are coincident with 
rising hCG levels (Surks et all., 2004). 
On Fig.2 is possible to see, how high is hCG in women with low TSH. (Springer et all., 2009) 
By using the classical reference interval for serum TSH one might misdiagnose as healthy 
those women who already have a slight TSH elevation and, conversely, one might suspect 
hyperthyroidism in normal women who have a lowered serum TSH value.  
Determining FT4 is by watching the amount of biologically active hormone which is 
available to the organism of a pregnant woman (as well as the fetus), and is not affected by 
the concentration of binding proteins. Its concentration during pregnancy is partly effected 
by inflow of iodine and the duration of the pregnancy. Free thyroxine levels remain within 
the normal range during pregnancy (though total thyroxine levels are increased secondary 
to increased TBG). Some consider it even more informative than TSH during pregnancy 
(Lazarus, 2002). During the 1st trimester, the fetus is completely dependent upon thyroxin 
produced by the mother. Even a small unnoticed malfunction of the thyroid gland, which 
doesn’t have to endanger the course of the pregnancy, can affect the psychomotor 
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development of the child. Early maternal hypothyroxinemia alters histogenesis and cerebral 
cortex cytoarchitecture of the progeny. 
 
 
Fig. 2. Free β hCG in groups with increasing TSH levels 
Anti-TPO antibodies (TPO Ab) are markers of autoimmune process in the thyroid gland, 
their determination is diagnostically and prognostically important. Presence of TPO Ab 
during pregnancy also alerts to the danger of development of postpartum tyreoiditidis; 
about 50% of TPO Ab positive women have some thyroid dysfunction after delivery, so it is 
necessary to follow-up these women. The relationship between TPO Ab and TSH is not 
definite, despite it being known that women with high level of TSH more frequently have 
positive TPO Ab.  
2.1.5 Reference intervals 
Reference intervals for different methods and manufacturer’s may vary, they have been 
established using pools of nonpregnant normal sera and with different antibodies. Such 
reference ranges are not valid during pregnancy. A reference interval is the range of values 
of a test result for a defined population. In older references the reference interval is often 
designated as the reference range. 
The main problem in setting of reference intervals for used laboratory markers is in case of 
using different immunoanalytic assays. Several factors can affect the setting of reference 
intervals, in particular manufacturer’s methodology, euthyroid definition and iodine status. 
Alterations in thyroid hormone concentrations during pregnancy differed at different stage 
of gestation and to those of a non-pregnant state. If the non-pregnant TSH reference range 
was applied to pregnant  women whose serum TSH concentration was within the first 
trimester specific reference range would be misclassified as having subclinical 
hyperthyroidism, or those with a TSH concentration above the first trimester specific upper 
reference limit would not be identified. 
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Determining the reference range suitable for the 1st trimester of pregnancy is possible by 
using the suggestion of the National Academy of Clinical Biochemistry (NACB) on selected 
samples from the population, or as 95th percentile from the cohort of women (Demers & 
Spencer, 2003). 
Evaluating thyroidal function during pregnancy is difficult, considering the other differing 
influences of pregnancy (Dayan et all., 2002). TSH regulation is based on feedback, however 
during pregnancy there are also other mechanisms taking place - mainly there is 
suppression of TSH, presumably due to a thyroid-stimulating activity of hCG early in 
pregnancy when hCG levels are the highest. (Goodwin et all., 1992). 
2.1.5.1 Determination of own reference intervals 
TSH, TPO Ab, and FT4 were assayed by ADVIA® Centaur™ (Siemens), with 
chemiluminometric detection. TSH was determined by sandwich imunoanalysis with direct 
chemiluminometric technology; for TPO Ab and FT4 competitive imunoanalysis with direct 
chemiluminometric technology was used.  
Reproducibility of this method is expressed by the interassay variability. For TSH, it is 5 - 
7% for levels of 0.43 – 15.00 mU/l; for TPO Ab it is 10% for the level of 70 kU/l and 7% for 
the level of 170 kU/l. Interassay variability for FT4 is 7 - 9% for levels 10.1 - 33.0 pmol/l. 
For mostly used systems were possible to use comparable TSH reference intervals, that were 
determined on large group of pregnant women (Springer et all., 2009). For evaluation of the 
reference interval, a selected group was created in accordance with the recommendations of 
the NACB. From the group of pregnant women (5,520), all those with a history of thyroid 
disease were excluded; TPO Ab > 60 kU/l (the manufacturer's cut-off) and free β hCG 
higher than triple of the median (Mdn=56.6 µg/l), in view of the suppression of TSH by a 
high level of hCG, were also excluded. TSH do not follow a normal distribution, data have 
to be normalized using log transformation. The reference interval - 95th percentile -was than 
determined using this log transformed data. The TSH reference interval for ADVIA:Centaur 
Siemens was determined to be 0.06 - 3.67 mU/l. 
FT4 levels fit a Gaussian distribution, so reference intervals were derived using 
nonparametric analyses such as the 95th percentile. The calculated reference interval (9.55 – 
23.0 pmol/l) was almost identical to the manufacturer’s (9.8 - 23.1 pmol/l) for all 
populations.  
Differences in TPO Ab manufacturer’s reference interval are not comparable from 0.5 to 100 
kU/l (Haddow et all., 2004; Hollowell et all., 2002; Negro et all., 2006). Reference intervals for 
thyroid antibody tests should be by the NACB recommendation; established from young male 
subjects, free from any history of thyroid disease or predisposition for any autoimmune 
disease (Demers & Spencer, 2003). Establishment of decision values for thyroid antibodies in 
the healthy population is difficult and results are method dependent (Jensen at all., 2006). The 
pregnancy positivity cut-off for TPO Ab was calculated at the 95th percentiles. From all of the 
women, women with a known history of thyroid disease were separated, as well as those with 
TSH lower than 0.1 and higher than 4.0 mU/l. This interval had been used earlier for the 
evaluation of positive results in pregnancy; it was deduced from both specialized literature 
and own experience. The positivity of TPO Ab in nonpregnant individuals is about 11% 
(Hollowell et all., 2002); in the pregnant population it is very similar. Negro mentioned 11.7% 
TPO Ab positive pregnant women (Negro et all., 2006); Dossiou selected groups by age and 
the positivity was 10.4 and 12.6 for ages 25 and 35 years, respectively (Dossiou et all., 2008). 
When was used the reference interval recommended by the producer of reagents (> 60 kU/l), 
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in study group was 22.1% positivity. If was used the 90th percentile (143 kU/l) as the cut-off for 
the group of pregnant women, was the positivity 11.2%. 
2.2 Results  
The pilot project for universal screening was performed during 2009-2010 in 13 regions of the 
Czech Republic with the financial support of the General Insurance Company. Cooperation in 
10 regions was good or suitable; 3 regions cooperated poorly and their data was not used in 
the first year of pilot project. In the second year were used only four laboratories for project. 
Thyroid examination was offered to women in the 9-11th week of pregnancy. The women with 
any positivity were offered immediate to endocrinological examination. Blood tests (TSH, FT4 
and TPO Ab) were carried out in 3577 asymptomatic pregnant women. 
On Fig. 3 is showed the map of Czech Republic with selected regions. The number under 
town name is number of implement investigations in the pilot project, the red one are 
excluded regions, green number included investigations also from second part of pilot 
project in 2010. 
 
 
Fig. 3. The map of Czech Republic with cooperating regions. Under name of the town are 
number of investigations, green number indicate laboratories worked on second part of 
levels. The red marked regions were excluded from statistic. 
There were used different analytical systems for analysis: the radio-imunoanalysis in five 
laboratories, chemilumino-imunoanalysis in six and electrochemilumino-imunoanalysis in 
two of them. Specific reference intervals for TSH, FT4, and positivity cut-off for TPO Ab 
during pregnancy were applied in all laboratories. 
In all 3577 women investigated in pilot project were found 679 (19.0%) pregnant women 
with some positivity.  
2.2.1 TSH 
A raised concentration of TSH was found in 7.63% of women; and a suppression of TSH was 
found in 3.05% of women. The prevalence of hypertyreosis in pregnant women is 1.7%, and 
0.4% of these women had an elevated serum FT4 level. This is similar to that reported for non-
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pregnant individuals. Low level of TSH with high FT4 level were only in 0.48%, which is in 
concordance with previous hypotheses, as well as with Haddow study (Haddow at all., 2004). 
Many authors have determined the prevalence of hypothyreosis (overt and subclinical) in 
pregnancy and it is estimated to be 0.3 - 0.5% for overt hypothyroidism and 2 - 3% for 
subclinical hypothyroidism (Haddow at all., 2004). In this study there were 7.63% of 
pregnant women with TSH over determined own reference interval; it is evident, that no all 
higher TSH means hypothyreosis. Also selection of pregnant women maybe was influenced 
by gynaecologists, which prefer high-risk women for investigation in pilot project.. On Fig. 4  
is schema with positivity in TSH levels: 
 
 
Fig. 4. Distribution of TSH levels in study group. 
2.2.2 FT4 
A raised concentration of FT4 was found in 0.48% of women; and a suppression of FT4 was 




Fig. 5. Distribution of FT4 in the study cohort.  
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Differences of FT4 in euthyroid women with suppressed, normal and elevated TSH were 
found and are showed on Fig. 6. 
 
 
Fig. 6. FT4 in euthyroid women with suppressed, normal and elevated TSH  
2.2.3 TPO Ab 
8.78% of pregnant women were found TPO Ab positive and there were also 5.4% of women, 
which had only TPO Ab positivity without another differences in TSH or FT4 levels. This 
distribution of results for whole study group is on Fig. 7 showed. 
 
 
Fig. 7. TPO Ab in whole study group  
2.3 General or only high-risk pregnant women testing? 
Presently available information that supports the hypothesis that an inappropriate first 
trimester surge in maternal FT4, whatever the circulating TSH, would interfere with the 
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development of the cerebral cortex, even if maternal euthyroidism is maintained by normal 
circulating T3. There is at present increasing consensus (Morreale et all., 2004) that maternal 
hypothyroidism, both clinical and subclinical, requires early detection and prompt 
treatment, because of its important negative effects for the woman, the pregnancy and the 
child. There also exists a positive association between the presence of thyroid antibodies and 
pregnancy loss with postpartum thyroiditis. 
The most practical approach is to screen all pregnant women for hypothyroidism as early in 
pregnancy as possible (or before conception). In the case of the mother, screening would 
reset in early diagnosis and treatment of subclinical hypothyroidism. Unfortunately, 
pregnant women with subclinical hypothyroidism seem to escape early clinical detection. In 
Mitchel study (Mitchel & Klein, 2004), 58% of the hypothyroid women were unaware of 
their disorder, and it took a median of 5 years from the time of the pregnancy for the clinical 
diagnosis to be made.  
Vaidya study shows that targeted thyroid function testing of only high-risk pregnant 
women would miss nearly one-third of women with overt/subclinical hypothyroidism 
during early pregnancy (Vaidya et all., 2007). In Czech Republic, case finding screening is 
able to disclose less than 20% of asymptomatic mild or deep hypothyroidism or women 
with positive TPO Ab in pregnancy (Springer et all., 2009).  
2.4 Relationship between TPO Ab and TSH, resp. FT4 
The relationship between TPO Ab and TSH is not definite, despite it being known that 
women with high level of TSH more frequently have positive TPO Ab. In study group, 
divided by serum TSH concentration, were 44.1% TPO Ab positive (in part), with TSH >3.67 
mU/l and 10.1% or 9.15% in the group with TSH < 0.06 mU/l or TSH in the reference 
interval, as is showed on Fig. 8. 
 
 
Fig. 8. TPO Ab in groups with different TSH level  
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Glinoer (Glinoer et all., 1995) also documented somewhat higher TSH levels among the sub-
population of women with elevated antibody levels and these findings are confirmed in the 
present study. 
Serum concentrations of FT4 were lower in TPO Ab positive as compared to TPO Ab 
negative women as is showed on Fig. 9. 
 
 
Fig. 9. Serum concentrations of FT4 in TPO Ab positive and TPO Ab negative women 
2.5 Cost effectiveness of the thyroid failure screening 
An answer to the question of screening cost-effectiveness of thyroid function in pregnancy 
was already presented by Dosiou (Dosiou et all., 2008). In this study is not defined cost-
efficiency, but it is unquestioned fact that early diagnosis of thyroid disorder is cost-effective 
and beneficial for both mother and child. 
3. Conclusion  
The importance of maternal thyroxine for the development of the fetus brain early in 
pregnancy has received increasing acceptance. It has more recently become evident that 
maternal hypothyroxinemia results in the birth of children with decreased mental and 
psychomotor development. 
This project proved the usefulness of universal screening of thyroid disease in pregnancy. 
The occurrence of pathological results in laboratory tests was 679/3577. Determination of 
the specific reference intervals for TSH, FT4, and TPO Ab in pregnancy is one of the basic 
requirements when implementing the general examination. Cooperation with 
gynaecologists differed, the main stumbling block was the willingness of gynaecologists to 
inform pregnant women about the project. 
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In Czech Republic, case finding screening is able to disclose less than 20% of asymptomatic 
mild or deep hypothyroidism or women with positive TPO Ab in pregnancy. Investigation 
of combination of TSH and TPO Ab is necessary. Maternal hypothyroxinemia appears to be 
a much more frequent cause of deficits in the progeny than congenital hypothyroidism, for 
which we have successful neonatal thyroid screening programs. This study maybe will help 
define the impact of universal screening (TSH, FT4, TPO Ab) on the health care system.  
The introduction of  general screening  of  thyroid failure in pregnancy needs to be  
emphasized  in public education; moreover, interdisciplinary cooperation of gynaecologist,  
endocrinologist and general practitioner, not to mention midwives should be improved. The 
other analysis would be more clearly identify the causal relationships between mild thyroid 
hormone deficiency and thyroid autoimmunity, on the one hand, and fetal neurological 
development on the other. In the meantime, physicians and obstetricians must use their own 
judgment about the optimal management for their individual patients. 
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